High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma

BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4(+) lymphocytes and their prognostic impact in lung cancer. We hypot...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Thorac Dis
Glavni autori: Karasaki, Takahiro, Qiang, Guangliang, Anraku, Masaki, Sun, Yanbin, Shinozaki-Ushiku, Aya, Sato, Eiichi, Kashiwabara, Kosuke, Nagayama, Kazuhiro, Nitadori, Jun-ichi, Sato, Masaaki, Murakawa, Tomohiro, Kakimi, Kazuhiro, Fukayama, Masashi, Nakajima, Jun
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129889/
https://ncbi.nlm.nih.gov/pubmed/30233846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.45
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items